Document is current

Article History

Received: 12 February 2025

Accepted: 12 August 2025

First Online: 21 August 2025

Change Date: 28 November 2025

Change Type: Update

Change Details: The original online version of this Article was revised: In the original version of this Article Affiliation 10 was incorrectly given as ‘Département de Santé Publique, Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Centre de Pharmacoépidémiologie de l’AP-HP (Cephepi), Paris, France’. The correct affiliation is listed as ‘Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Paris, France’.

Declarations

:

: C.G.-V. has received honoraria for talks on behalf of Gilead Sciences, MSD, Pfizer, Jansen, Novartis, Basilea, GSK, Shionogi, AbbVie and Advanz Pharma, and grant support from Gilead Sciences, Pfizer, GSK, MSD and PharmaMar. KL has received honoraria and grant support outside of the topic of this manuscript by Gilead, MSD and ViiV Healthcare. All other authors do not declare any conflict of interest.

: All other authors do not declare any conflict of interest.